Modified immune cells and uses thereof

By modifying immune cells to reduce target protein expression and function using CRISPR/Cas9 and CARs, the persistence and efficacy of allogeneic CAR-T and CAR-NK cells are enhanced, addressing HvG and AICD challenges for improved cancer treatment.

JP2025535133APending Publication Date: 2025-10-22PEKING UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2025521241
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-08-02
Filing Date
2023-10-12
Publication Date
2025-10-22

AI Technical Summary

Technical Problem

The poor persistence and susceptibility to host-versus-graft (HvG) responses and activation-induced cell death (AICD) of allogeneic CAR-T and CAR-NK cells limit their therapeutic efficacy and applicability in cancer treatment, due to host immune recognition and self-killing mechanisms.

Method used

Immune cells are modified to reduce or eliminate the expression and function of proteins such as SPPL3, FADD, FAS, CASP8, ARID1A, BAK1, BID, ETS1, and IKZF2 through gene editing techniques like CRISPR/Cas9, and engineered to express chimeric antigen receptors (CARs) while maintaining functionality, thereby enhancing persistence and reducing AICD.

Benefits of technology

The modified immune cells exhibit prolonged in vivo persistence, reduced AICD, and decreased host immune rejection, improving therapeutic efficacy and applicability across a broader patient population.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2025535133000003
    Figure 2025535133000003
  • Figure 2025535133000004
    Figure 2025535133000004
  • Figure 2025535133000005
    Figure 2025535133000005
Patent Text Reader

Abstract

The present application relates to immune cells (e.g., T cells such as CAR-T cells, NK cells such as CAR-NK cells) modified to have absent or reduced expression and / or function of one or more target proteins selected from the group consisting of signal peptide peptidase-like 3 (SPPL3), FADD, FAS, CASP8, ARID1A, BAK1, BID, ETS1, IKZF2, and HIST1H1B (e.g., SPPL3), uses thereof, and methods for producing same. Also provided is the use of one or more target proteins (e.g., SPPL3) as a biomarker.
Need to check novelty before this filing date? Find Prior Art